Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Agnelli, 1998 - enoxaparin vs Placebo

Nurmohamed, 1996 - nadroparin vs Placebo

Melon, 1987 - enoxaparin vs Placebo

Cerrato, 1978 - UFH vs no treatment



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of LMWH
  • All clinical trials of enoxaparin
    		•  

    Melon study, 1987

    Treatments

    Studied treatment Enoxaparin, 20 mg/d subcutaneously 18-24 hours postoperatively for 10 days
    Control treatment placebo

    Patients

    Patients Neurosurgery, adult, 45-90 kg of weight, without excess bleeding risk
    Baseline characteristics
    Endpoint assessment Venography 

    Method and design

    Randomized effectives 67 / 63 (studied vs. control)
    Follow-up duration NA


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    Bleeding

    0 / 67
         0 / 63
         classic 0,94 [0,00;237,81]

    Major bleeding

    0 / 67
         0 / 63
         classic 0,94 [0,00;237,81]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    Major bleeding 0 / 67 (0,7%) 0 / 63 (0,8%) 0,94 [0,02;46,68]    
    Bleeding 0 / 67 (0,7%) 0 / 63 (0,8%) 0,94 [0,02;46,68]    
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.


    Reference(s)

    Trials register # NA
    • Melon E, Keravel Y, Gaston A, Huet Y, Combes S, and the NEURONOX groupj. Deep venous thrombosis prophylaxis by low molecular weight heparin in neurosurgical patients [abstract. Anesthesiology. 1987;75:A214
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend